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H
elicobacter pylori is one of the most common bacterial pathogens, affecting more than half of the population worldwide. 1 This bacterium was first described as a member of the genus Campylobacter; however, because of differences in taxonomy, it was classified as a member of the genus Helicobacter in 1989. 2 Despite its widespread prevalence, clinical manifestations of the organism develop in a minority of cases.
Helicobacter pylori is the most common cause of gastric and duodenal ulcers, especially when nonsteroidal anti-inflammatory drug use has been ruled out. 3 In individuals infected with H pylori, there is a 10% to 20% lifetime risk of peptic ulcer disease (PUD) and 1% to 2% risk of gastric cancer. 3 Specifically, patients infected with cytotoxinassociated gene A H pylori strains are at higher risk of PUD and gastric cancer because of greater inflammation. 3 Recognizing H pylori in the right clinical circumstances is crucial, as treatment can greatly decrease morbidity. For example, eradication of H pylori in patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma can lead to 60% to 80% regression of the lymphoma. 3 
EPIDEMIOLOGY
In developing countries, infection commonly develops in children and chronic infection continues into adulthood; in the developed world, infection is rare in children and develops more commonly in adulthood. 3 Early exposure to H pylori is associated with gastric pathologic changes, progressing from atrophic gastritis to gastric ulcers and carcinoma. 4 Later-onset infection most commonly presents with duodenal pathology. 4 The most common route of transmission is person-to-person spread through fecal-oral and oral-oral exposures. 4 The prevalence of infection generally increases with age and is higher in blacks and Hispanics than in whites. 5, 6 The seroprevalence of H pylori is approximately 30% in individuals younger than 30 years and 63% for individuals aged 55 to 65 years. 5 In addition, H pylori prevalence varies by ethnic groups: whites, 26%; blacks, 53%; and Mexican Americans, 62%. 6 Risk factors for transmission are related to living conditions that promote close personto-person contact such as crowded homes and sharing of beds. 5 The association of these factors with socioeconomic status may explain some of the racial differences in H pylori prevalence in the United States.
PATHOGENESIS
Helicobacter pylori is a spiral, microaerophilic, gram-negative bacterium with flagella that have urease, catalase, and oxidase activity. These characteristics are vital to its survival in the harsh acidic gastric environment. Specifically, urease helps convert urea to ammonia, which aids in neutralizing gastric acid and promoting bacterial protein synthesis. 7 The gene urel encodes for a hydrogen ionegated urea channel that promotes urea uptake and urease secretion in response to a decrease in gastric pH. 7 Urease can account for up to 10% of the total protein content of H pylori. 8 Helicobacter pylori infection triggers an intense release of phagocytic cells that attempt to kill the organism by releasing oxygen metabolites. 9 However, catalase activity enables H pylori to survive this oxidative stress. 9 In turn, the inflammatory response damages the gastric epithelial lining and allows H pylori to flourish. In addition, flagellamediated motility allows for the colonization of the stomach mucosa and facilitates initial infection. Helicobacter pylori infection predominantly affecting the gastric corpus is associated with hypochlorhydria because of damage to parietal cells, whereas infection localized to the gastric antrum is associated with duodenal ulceration given an increase in gastrin production may be seen. 3 
DIAGNOSIS
Because of the strong association of H pylori with PUD and MALT lymphoma, H pylori testing is recommended for patients with a history of or active PUD and MALT lymphoma (Figure) . 10 In addition, H pylori testing should be performed in patients with dyspepsia if the local H pylori prevalence exceeds 10%. 11 In such patients who are younger than 60 years and without alarm features, a test-and-treat approach to H pylori is effective. 10 Alarm features include fevers, weight loss, anemia, gastrointestinal bleeding, dysphagia, and personal or family history of malignant neoplasm. In patients aged 60 years or older and in those with alarm features, esophagogastroduodenoscopy is the most appropriate first step. Regional H pylori prevalence patterns are poorly described in the literature. In the United States, estimates of H pylori prevalence approach 30%. 12 Patients from lower socioeconomic backgrounds, those from poor living conditions, or those immigrated from a region with high prevalence are at higher risk and should have a lower threshold for being tested. Testing should not be performed in asymptomatic family members unless there are known risk factors, such as a family history of gastric malignant neoplasm. 10 Helicobacter pylori infection can be diagnosed using noninvasive and invasive methods. In general, both noninvasive and invasive tests are equally accurate. 13 Noninvasive tests include the urea breath test, fecal antigen test, and serologic test. The preferred noninvasive tests in the outpatient setting are the urea breath test and fecal antigen test given their excellent accuracy and ability to diagnose active infection. The fecal antigen test relies on identifying H pylori antigens in the stool using an enzymatic immunoassay. 13 In the urea breath test, urea labeled with 13C or 14C is given to patients. Urease, if present, converts urea into ammonia and labeled CO 2 that is exhaled, indicating a positive result. 13 Before testing, proton pump inhibitors (PPIs) and antibiotics should be discontinued at least 2 and 4 weeks, respectively, as these can interfere with the urea test. 10 Pretreatment sensitivity and specificity of both these tests are approximately 95%. 13 Although the cost of testing varies by location and laboratory, the estimated cost of the urea breath test and fecal antigen test is $102.80 and $19.70, respectively.
14 Serologic testing is not recommended to detect active infection, as it cannot distinguish between active disease and previous exposure. Antibodies to H pylori can remain elevated for a long time even after treatment, potentially increasing the number of false-positive results. 13 The 1 positive aspect of serologic testing is that it is the only test for H pylori that is not affected by PPI therapy, antibiotics, or by the presence of blood in the stomach.
Invasive testing strategies require upper endoscopy and include the biopsy urease (campylobacter-like organism) test, histologic assessment, and culture. The biopsy urease test is a good first-line test, as it is accurate, rapid, and inexpensive. This test relies on H pylori urease to convert urea into ammonia, increase the pH, and change the color of the pH indicator. 15 Although the specificity is excellent with this test (>95%), the sensitivity can vary from 75% to 98%. 15 The urease test is preferred in patients without recent use of PPIs and antibiotics, as outlined above. 10 However, in patients with recent PPI or antibiotic use, histologic assessment of biopsy samples is the better choice, although these medications can interfere with bacterial density. 10 Traditionally, histologic assessment is the criterion standard for the diagnosis of H pylori infection. One advantage of the histological test over other modalities is that it allows for the examination of inflammation, metaplasia, dysplasia, and malignant neoplasm. The results of the histological test can vary depending on the number and location of biopsy samples obtained, the experience of the gastroenterologist and pathologist, and the type of stain used. Immunostaining for H pylori can be done in addition to routine hematoxylin and eosin staining to improve the yield from histologic assessment. Although culture and sensitivity testing is routinely performed for most bacterial infections, it is rarely performed for H pylori because of a prolonged incubation period of up to 2 weeks. 15 However, the use of culture can play an important role in certain circumstances, such as in the patient who has failed to respond to therapy in order to identify potential antibiotic resistance and select an alternative treatment regimen. 10-to 14-day course of standard triple therapy, which consists of a PPI, amoxicillin, and clarithromycin. In patients with penicillin allergy, the recommended treatment options include a 10-to 14-day course of bismuth quadruple therapy, which consists of a PPI, bismuth, metronidazole, and tetracycline (PBMT) or a 10-to 14-day course of a PPI, clarithromycin, and metronidazole. 10 Over the past several years, clarithromycin resistance is increasing worldwide while H pylori eradication rates are decreasing. 16 Data on clarithromycin resistance in the United States remains limited, but estimates approach 30%. 16 Consequently, alterative regimens have been suggested to counteract this increase in resistance. One proposed regimen is sequential therapy, which consists of a PPI and amoxicillin for the first half of treatment duration and a PPI, metronidazole, and clarithromycin for the second half. The principle behind sequential therapy is that amoxicillin first weakens the bacterial cell wall, which then allows clarithromycin and metronidazole to directly attack the bacteria and prevent efflux of antibiotics through drug efflux channels. Although this principle makes theoretical sense, a 10-day course of reverse sequential therapy (5 days of a PPI, clarithromycin, and metronidazole followed by 5 days of a PPI and amoxicillin) had an eradication rate similar to that of a 10-day course of standard sequential therapy. 17 Another regimen is concomitant nonbismuth therapy, which consists of a PPI, amoxicillin, metronidazole, and clarithromycin (PAMC). The notion with this therapy is that the addition of a third antibiotic compared with standard triple therapy should result in higher eradication rates.
TREATMENT
Several studies have analyzed the various treatment regimens in different populations over the past decade. A pooled data analysis 18 comparing a 7-to 10-day course of standard triple therapy with a 10-day course of sequential therapy revealed higher rates of eradication in the sequential therapy group, consistently greater than 90%. A multicenter randomized controlled trial (RCT) 19 compared 7-day courses of standard triple therapy and concomitant (PAMC) therapy with a 10-day course of sequential therapy and found that concomitant therapy had the highest eradication rates. Intention-to-treat (ITT) eradication rates with PPI, amoxicillin, and clarithromycin therapy; sequential therapy; and concomitant therapy were 76.2%, 84.4%, and 94.4%, respectively. 19 Another RCT 20 compared 10-and 14-day sequential therapy with 10-and 14-day concomitant PAMC therapy and found ITT rates of 91.7%, 91.2%, 94.2%, and 98.5%, respectively. More recently, a multicenter, open-label, RCT 21 comparing the efficacy of 10-day bismuth quadruple PBMT therapy, 10-day concomitant PAMC therapy, and 14-day standard triple therapy found eradication rates of 90.4%, 85.9%, and 83.7%, respectively. There was a statistically significant difference between quadruple PBMT therapy and standard triple therapy but not between quadruple PBMT therapy and concomitant PAMC therapy. 21 However, not all studies have reported a difference in eradication between various treatment options. A Cochrane Database Systematic Review 22 found no differences in efficacy between 10-day regimens of sequential therapy and standard triple therapy.
New guidelines have also been proposed to reflect the increasing clarithromycin resistance patterns. The 2016 Toronto Consensus guidelines 23 recommend first-line treatment with a 14-day course of either concomitant PAMC therapy or bismuth quadruple PBMT therapy. The 2016 Maastricht V/Florence Consensus Report 24 recommends first-line treatment with a 14-day course of bismuth quadruple PBMT therapy or concomitant PAMC therapy in areas of high clarithromycin resistance (>15% resistance). However, standard triple therapy and bismuth quadruple PBMT therapy are acceptable first-line regimens in areas of low clarithromycin resistance (<15% resistance). 24 Both guidelines 23, 24 recommend all treatment regimens be 14 days in duration and standard triple therapy be abandoned in areas of high clarithromycin resistance. A Cochrane Database Systematic Review 25 analyzed the optimal duration of the treatment of H pylori infection and determined that 14-day therapy was ideal. Compared with 7-day regimens, 14-day regimens achieved significantly higher rates of eradication (72.9% versus 81.9%), with a relative risk of H pylori persistence of 0.66 (95% CI 0.60-0.74). 25 Given the increase in clarithromycin resistance worldwide and limited knowledge about local antibiotic resistance patterns, we believe that first-line treatment should consist of a 14-day course of concomitant PAMC therapy or bismuth quadruple PBMT therapy, consistent with these newer guidelines (Table) . Recent research has continued to explore new potential treatment options for H pylori infection. Vonoprazan is a new potassiumcompetitive acid suppressing medication. A multicenter retrospective study 26 found considerably higher eradication rates with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) than with standard triple therapy: 87.2% vs 72.4%, respectively. Another proposed approach to the treatment of H pylori infection is based on culture-based antimicrobial susceptibilityguided therapy. One study compared concomitant PAMC therapy with susceptibility-guided triple therapy with a PPI, amoxicillin, and one of the following: clarithromycin, levofloxacin, and metronidazole. The last one achieved higher eradication rates with ITT analysis: 94% vs 87%. 27 Moreover, the addition of probiotics to H pylori antibiotic regimens has resulted in better treatment efficacy as compared with placebo (87.4% vs 72.6%) and fewer medication adverse effects. 28 The American College of Gastroenterology 10 recommends eradication confirmation testing in the following groups of patients: those with persistent symptoms despite treatment, H pylorieinduced ulcer, MALT lymphoma, and early resection for gastric cancer. However, given the increasing H pylori resistance worldwide, eradication confirmation testing should ideally be performed in all patients undergoing treatment, at least 4 weeks after the completion of therapy. This time frame is critical, as enough time is necessary for any surviving bacteria to populate the gastric environment and become detectable on repeat testing. In addition to antibiotic resistance, other causes of treatment failure include nonadherence to drug therapy and short treatment duration. In addition, eradication confirmation testing, when performed universally, has been found to be cost-effective. 14 Because noninvasive tests are both accurate and relatively inexpensive, repeat testing should be performed with a urea breath test or fecal antigen test, because they are the 2 noninvasive tests that detect active infection. Serologic testing is not appropriate for eradication confirmation, as it does not distinguish between active and previous infections. Invasive testing with upper endoscopy should rarely be considered for eradication confirmation and should be limited to instances in which there are other indications for upper endoscopy (such as documenting healing of a large ulcer or sampling of a gastric ulcer not previously sampled).
CONCLUSION
Helicobacter pylori is a complex bacterial pathogen and a leading causative agent of gastritis, PUD, and gastric lymphoma worldwide. Infection is common in both developing and developed countries. Its unique characteristics, including urease activity, allow it to thrive in the harsh acidic gastric environment. In the outpatient setting, the diagnosis can be easily and accurately performed with the urea breath test or fecal antigen test. With increasing H pylori resistance to traditional antibiotic 
